- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
November 2019
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Allergan Sales, LLC v. Ajanta Pharma Ltd., 19-1249 (D. Del.) | July 2, 2019 | Hon. Leonard P. Stark | Bystolic® (nebivolol HCl tablets) | 6,545,040 |
| Teva Pharms. Int’l Gmbh v. Lupin, Ltd., 19-1251 (D. Del.) | July 2, 2019 | Hon. Colm F. Connolly | Bendeka® (bendamustine HCl for injection) | 8,609,707 9,265,831 9,572,796 9,572,797 9,034,908 9,144,568 9,572,887 9,597,397 9,597,398 9,597,399 9,000,021 9,579,384 10,010,533 10,052,385 |
| Celgene Corp. v. Cipla Ltd., 19-14731 (D.N.J.) | July 3, 2019 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,465,800 7,855,217 7,968,569 8,530,498 8,648,095 9,101,621 9,101,622 7,189,740 8,404,717 9,056,120 |
| AstraZeneca LP v. HEC Pharm Co., Ltd., 19-14737 (D.N.J.) | July 3, 2019 | Hon. Claire C. Cecchi | Brilinta® (ticagrelor tablets) | RE46,276 7,265,124 |
| Leo Pharma A/S v. Teva Pharms. USA, Inc., 19-1282 (D. Del.) | July 9, 2019 | Hon. Colm F. Connolly | Finacea® (azelaic acid foam) | 10,322,085 |
| Boehringer Ingelheim Pharms. Inc. v. Zydus Pharms. (USA) Inc., 19-1295 (D. Del.) | July 11, 2019 | Hon. Colm F. Connolly | Glyxambi® (empagliflozin / linagliptin tablets) | 7,579,449 7,713,938 8,551,957 9,949,998 10,258,637 |
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 19-15343 (D.N.J.) | July 12, 2019 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 8,198,262 8,673,939 8,735,428 8,828,427 9,993,467 |
| Actelion Pharms. Ltd. v. Aurobindo Pharma USA Inc., 19-15437 (D.N.J.) | July 16, 2019 | Hon. Freda L. Wolfson | Opsumit® (macitentan tablets) | 7,094,781 |
| Cubist Pharms. LLC v. Amneal Pharms. LLC, 19-15439 (D.N.J.) | July 16, 2019 | Hon. Brian R. Martinotti | Cubicin RF® (daptomycin for injection) | 9,138,456 |
| Teijin Ltd. v. Sunshine Lake Pharma Co., Ltd., 19-15448 (D.N.J.) | July 16, 2019 | Hon. Michael A. Shipp | Uloric® (febuxostat tablets) | 7,361,676 8,372,872 9,107,912 |
| Celgene Corp. v. Hetero Labs Ltd., 19-15449 (D.N.J.) | July 16, 2019 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,189,740 7,968,569 8,404,717 8,530,498 8,648,095 9,056,120 9,101,621 9,101,622 |
| Ajanta Pharma Ltd. v. Pfizer Inc., 19-6607 (S.D.N.Y.) | July 16, 2019 | Hon. Jesse M. Furman | Chantix® (varenicline tablets) | 6,890,927 7,265,119 |
| UCB, Inc. v. Mylan Technologies, Inc., 19-0128 (D. Vt.) | July 16, 2019 | Hon. John M. Conroy | Neupro® (rotigotine transdermal system) | 10,130,589 10,350,174 |
| Eisai Co., Ltd. v. Lupin Ltd., 19-1336 (D. Del.) | July 17, 2019 | Hon. Leonard P. Stark | Banzel® (rufinamide oral suspension) | 6,740,669 |
| Alkermes Pharma Ireland Ltd. v. Luye Pharma Group Ltd., 19-1340 (D. Del.) | July 17, 2019 | Hon. Leonard P. Stark | Risperdal Consta® (extended-release risperidone for injection) | 6,667,061 |
| Mitsubishi Tanabe Pharma Corp. v. MSN Labs. Private Ltd., 19-15616 (D.N.J.) | July 19, 2019 | Hon. Peter G. Sheridan | Invokamet XR® (canagliflozin / metformin HCl extended-release tablets) | 7,943,582 8,513,202 |
| Braintree Labs., Inc. v. Hetero Labs Ltd., 19-15676 (D.N.J.) | July 22, 2019 | Hon. Michael A. Shipp | Suprep® (sodium sulfate / potassium sulfate / magnesium sulfate oral lavage solution) | 6,946,149 |
| Corcept Therapeutics, Inc. v. Sun Pharma Global FZE, 19-15678 (D.N.J.) | July 22, 2019 | Hon. Susan D. Wigenton | Korlym® (mifepristone tablets) | 8,921,348 10,195,214 9,829,495 |
| AstraZeneca LP v. Dr. Reddy’s Labs., Ltd., 19-15739 (D.N.J.) | July 23, 2019 | Hon. Claire C. Cecchi | Brilinta® (ticagrelor tablets) | RE46,276 |
| Bayer Intellectual Property Gmbh v. Sunshine Lake Pharma Co., Ltd., 19-1448 (D. Del.) | Aug. 1, 2019 | Hon. Timothy Belcher Dyk | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Vifor (Int’l) AG v. Sandoz Inc., 19-16305 (D.N.J.) | Aug. 2, 2019 | Hon. Freda L. Wolfson | Injectafer® (ferric carboxymaltose for injection) | 7,612,109 7,754,702 8,895,612 9,376,505 |
| Janssen Pharms., Inc. v. Mylan Labs. Ltd., 19-16484 (D.N.J.) | Aug. 8, 2019 | Hon. Claire C. Cecchi | Invega Sustenna® (paliperidone palmitate extended-release injectable suspension) | 9,439,906 |
| Abraxis Bioscience, LLC v. Sun Pharma Advanced Research Co., Ltd., 19-16495 (D.N.J.) | Aug. 8, 2019 | Hon. Stanley R. Chesler | Abraxane® (paclitaxel protein-bound particles for injectable suspension) | 7,758,891 7,820,788 7,923,536 8,034,375 8,138,229 8,268,348 8,314,156 8,853,260 9,101,543 9,393,318 9,511,046 9,597,409 |
| Janssen Pharms., Inc. v. Mylan Labs. Ltd., 19-1488 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Invega Sustenna® (paliperidone palmitate extended-release injectable suspension) | 9,439,906 |
| Par Pharm., Inc. v. American Regent, Inc., 19-1490 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Vasostrict® (vasopressin for injection) | 9,375,478 9,687,526 9,744,209 9,750,785 |
| Boehringer Ingelheim Pharms. Inc. v. Aizant Drug Research Solutions Prv. Ltd., 19-1492 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Alkem Labs. Ltd., 19-1493 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Cipla Ltd., 19-1494 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Synjardy® XR (empagliflozin / metformin extended-release tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Dr. Reddy’s Labs., Ltd., 19-1495 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Invagen Pharms., Inc., 19-1496 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Lupin Ltd., 19-1497 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Mankind Pharma Ltd., 19-1498 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Prinston Pharm. Inc., 19-1499 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Glyxambi® (empagliflozin / linagliptin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Sun Pharm. Indus. Ltd., 19-1500 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Glyxambi® (empagliflozin / linagliptin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Zydus Pharms. (USA) Inc., 19-1501 (D. Del.) | Aug. 9, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) Synjardy® (empagliflozin / metformin tablets) | 10,258,637 |
| Janssen Pharms., Inc. v. Mylan Labs. Ltd., 19-0153 (N.D.W.V.) | Aug. 9, 2019 | Hon. Thomas S. Kleeh | Invega Sustenna® (paliperidone palmitate extended-release injectable suspension) | 9,439,906 |
| Novo Nordisk Inc. v. Mylan Institutional LLC, 19-1551 (D. Del.) | Aug. 20, 2019 | Hon. Colm F. Connolly | Victoza® (liraglutide recombinant solution for injection) | 6,268,343 7,762,994 8,114,833 8,579,869 8,846,618 9,265,893 RE41,956 |
| Novo Nordisk Inc. v. Mylan Institutional LLC, 19-0164 (N.D.W.V.) | Aug. 22, 2019 | Hon. Thomas S. Kleeh | Victoza® (liraglutide recombinant solution for injection) | 6,268,343 7,762,994 8,114,833 8,579,869 8,846,618 9,265,893 RE41,956 |
| Currax Pharms. LLC v. Zydus Pharms. (USA) Inc., 19-1569 (D. Del.) | Aug. 23, 2019 | Hon. Richard G. Andrews | Silenor® (doxepin HCl tablets) | 8,513,299 9,107,898 9,486,437 9,532,971 9,861,607 9,907,780 10,238,620 |
| Assertio Therapeutics Inc. v. Alkem Labs. Ltd., 19-17170 (D.N.J.) | Aug. 23, 2019 | Hon. Claire C. Cecchi | Nucynta® ER (tapentadol HCl extended-release tablets) | 8,309,060 |
| Boehringer Ingelheim Pharms. Inc. v. Annora Pharma Private Ltd., 19-1594 (D. Del.) | Aug. 28, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 10,258,637 |
| Boehringer Ingelheim Pharms. Inc. v. Laurus Labs Ltd., 19-1596 (D. Del.) | Aug. 28, 2019 | Hon. Colm F. Connolly | Jardiance® (empagliflozin tablets) | 10,258,637 |
| Bial – Portela & CA. S.A. v. Torent Pharms. Ltd., 19-1673 (D. Del.) | Sept. 6, 2019 | Hon. Colm F. Connolly | Aptiom® (eslicarbazepine acetate tablets) | 9,750,747 |
| Allergan USA, Inc. v. Aurobindo Pharma Ltd., 19-1674 (D. Del.) | Sept. 6, 2019 | Hon. Richard G. Andrews | Viberzi® (eluxadoline tablets) | 7,741,356 7,786,158 8,344,011 8,609,709 8,772,325 9,205,076 9,700,542 10,213,415 |
| Amgen Inc. v. The ACME Labs. Ltd., 19-1702 (D. Del.) | Sept. 11, 2019 | Hon. Mitchell S. Goldberg | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Allergan USA, Inc. v. Aurobindo Pharma Ltd., 19-1727 (D. Del.) | Sept. 13, 2019 | Hon. Richard G. Andrews | Viberzi® (eluxadoline tablets) | 8,691,860 9,115,091 9,364,489 9,675,587 9,789,125 10,188,632 |
| Genzyme Corp. v. Aizant Drug Research Solutions Private Ltd., 19-1734 (D. Del.) | Sept. 16, 2019 | Hon. Colm F. Connolly | Cerdelga® (eliglustat tablets) | 6,916,802 7,253,185 7,615,573 |
| Boehringer Ingelheim Pharms. Inc. v. Macleods Pharms. Ltd., 19-1772 (D. Del.) | Sept. 20, 2019 | Hon. Colm F. Connolly | Tradjenta® (linagliptin tablets) | 8,673,927 8,853,156 9,173,859 |
| Horizon Medicines LLC v. Ajanta Pharma Ltd., 19-1814 (D. Del.) | Sept. 27, 2019 | Hon. Richard G. Andrews | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 9,345,695 8,852,636 8,858,996 9,161,920 9,198,888 9,707,181 |
| Horizon Medicines LLC v. Ajanta Pharma Ltd., 19-18555 (D.N.J.) | Sept. 30, 2019 | Hon. Brian R. Martinotti | Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) | 9,345,695 8,852,636 8,858,996 9,161,920 9,198,888 9,707,181 |
| Chiesi USA Inc. v. MSN Pharms. Inc., 19-18564 (D.N.J.) | Sept. 30, 2019 | Hon. Madeline Cox Arleo | Kengreal® (cangrelor for injection) | 8,680,052 9,295,687 9,427,448 9,439,921 9,700,575 9,925,265 10,039,780 |
| Chiesi USA Inc. v. Gland Pharma Ltd., 19-18565 (D.N.J.) | Sept. 30, 2019 | Hon. Madeline Cox Arleo | Kengreal® (cangrelor for injection) | 9,295,687 |
| Salix Pharms., Ltd. v. Sandoz Inc., 19-18566 (D.N.J.) | Sept. 30, 2019 | Hon. Michael A. Shipp | Xifaxan® (rifaximin tablets) | 7,045,620 7,612,199 7,902,206 7,906,542 7,915,275 8,158,644 8,158,781 8,193,196 8,309,569 8,518,949 8,741,904 8,835,452 8,853,231 9,271,968 |
GENERICally Speaking Fall 2019
Related Professionals
Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.